The Zhitong Finance App learned that Rongchang Biotech (09995) rose more than 5% in the morning. As of press release, it had risen 5.6% to HK$83.95, with a turnover of HK$298 million.

According to the news, Rongchang Biotech announced Yingxi. It expects revenue for the first half of the year to be about 5.850 billion yuan, an increase of more than 4.3 times over the previous year; it is estimated to achieve net profit of 4.7 billion yuan, or about 4.300 billion yuan after deducting non-return net profit. Judging from the scale comparison, the company's forecast revenue for the first half of the year has already exceeded the revenue level for the whole year of 2025, and the profit scale is also significantly higher than the net profit returned to mother for the full year of 2025. This is the first time since the company went public that it has achieved large-scale profits in the interim report.

According to the announcement, the increase in performance was mainly due to the continuous increase in domestic sales revenue of the core commercial products taitacip and verdicitumab; second, the exclusive licensing agreement between RC148 and AbbVie outside of Greater China led to confirmation of large technical licensing revenue, which became the core incremental source of profit for the current period. According to reports, in January of this year, Rongchang Biotech and AbbVie signed an overseas rights license for RC148 (PD-1/VEGF dual antibody), with a total transaction amount of up to 5.6 billion US dollars.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.